PMID- 14698650
OWN - NLM
STAT- MEDLINE
DCOM- 20041214
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 111
IP  - 6
DP  - 2003
TI  - Signs of thrombin generation in pediatric cardiac catheterization with 
      unfractionated heparin bolus or subcutaneous low molecular weight heparin for 
      antithrombotic cover.
PG  - 335-41
AB  - INTRODUCTION: Thrombosis is one of the most frequent adverse events after cardiac 
      catheterization, which can be reduced by anticoagulation with unfractionated 
      heparin (UFH) in both children and adults. Low molecular weight heparin (LMWH) 
      might possibly offer advantages. Laboratory signs of thrombin generation during 
      pediatric cardiac catheterization, with unfractionated heparin (UFH) bolus or 
      subcutaneous LMWH for thrombosis prophylaxis, were determined in a first step to 
      investigate the potential of LMWH for antithrombotic cover. MATERIALS AND 
      METHODS: Signs of thrombin generation (D-dimer and F1+2), anti-Xa activity and 
      activated clotting time (ACT) were measured in 65 patients with congenital heart 
      disease. A total of 40 patients were treated with a UFH bolus of 100 IU/kg 
      bodyweight and, in 25 children, enoxaparin was subcutaneously administered at a 
      dosage of 1/1.6 mg/kg bodyweight. RESULTS: The dose to plasma activity of 
      enoxaparin was more consistent than in the UFH group. Only a slight elevation of 
      F1+2 was found in some patients, which was a little higher in the enoxaparin 
      group, but no difference of incidence of increased F1+2 generation was detected 
      between the two groups. D-dimer was elevated in three children after UFH bolus 
      application, but no such effect was observed in any child after LMWH 
      administration. CONCLUSIONS: Application of LMWH was equally efficacious during 
      pediatric cardiac catheterization than UFH bolus administration, as determined by 
      plasma levels and markers of clotting activation. In contrast to UFH bolus, no 
      further monitoring was necessary after the application of LMWH during cardiac 
      catheterization due to a consistent dose to plasma activity.
FAU - Roschitz, Birgit
AU  - Roschitz B
AD  - Ludwig Boltzmann Research Institute for Pediatric Thrombosis and Hemostasis, 
      Division of Pediatric Cardiology, Graz, Austria.
FAU - Beitzke, Albrecht
AU  - Beitzke A
FAU - Gamillscheg, Andreas
AU  - Gamillscheg A
FAU - Sudi, Karl
AU  - Sudi K
FAU - Koestenberger, Martin
AU  - Koestenberger M
FAU - Leschnik, Bettina
AU  - Leschnik B
FAU - Muntean, Wolfgang
AU  - Muntean W
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.5 (Thrombin)
SB  - IM
MH  - Adolescent
MH  - Anticoagulants/*administration & dosage
MH  - *Cardiac Catheterization/adverse effects/*methods
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Heparin/*administration & dosage
MH  - Heparin, Low-Molecular-Weight/*administration & dosage
MH  - Humans
MH  - Infant
MH  - Injections, Subcutaneous
MH  - Male
MH  - Thrombin/*biosynthesis
MH  - Thromboembolism/*prevention & control
EDAT- 2003/12/31 05:00
MHDA- 2004/12/16 09:00
CRDT- 2003/12/31 05:00
PHST- 2003/12/31 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2003/12/31 05:00 [entrez]
AID - S0049384803005048 [pii]
AID - 10.1016/j.thromres.2003.09.020 [doi]
PST - ppublish
SO  - Thromb Res. 2003;111(6):335-41. doi: 10.1016/j.thromres.2003.09.020.